Plasma miR‑145, miR‑20a, miR‑21 and miR‑223 as novel biomarkers for screening early‑stage non‑small cell lung cancer

Zhang,Hui; Mao,Feng; Shen,Tuyang; Luo,Qingquan; Ding,Zhengping; Qian,Liqiang; Huang,Jia

doi:10.3892/ol.2016.5462

Plasma miR‑145, miR‑20a, miR‑21 and miR‑223 as novel biomarkers for screening early‑stage non‑small cell lung cancer

Authors:
- Hui Zhang
- Feng Mao
- Tuyang Shen
- Qingquan Luo
- Zhengping Ding
- Liqiang Qian
- Jia Huang
View Affiliations

Affiliations: Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Lung Tumor Clinical Medical Center, Shanghai Jiaotong University, Shanghai 200030, P.R. China
Published online on: December 6, 2016 https://doi.org/10.3892/ol.2016.5462
Pages: 669-676
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑small cell lung cancer (NSCLC) is the leading cause of cancer‑related mortality in the world. Late diagnosis is one of the most significant reasons for the high mortality rate of lung cancer. The identification of microRNAs (miRNAs) has opened a new field for molecular diagnosis of cancer. The purpose of the present study was to investigate whether plasma miRNAs may be used as biomarkers for early‑stage NSCLC. A total of 232 participants, including 149 NSCLC patients and 83 healthy controls, were recruited between July 2012 and May 2014. We measured the levels of 10 miRNAs (miR‑30d, miR‑383, miR‑20a, miR‑145, miR‑221, miR‑25, miR‑223, miR‑21, miR‑126 and miR‑210) in plasma samples of 40 individuals (20 patients and 20 matched healthy controls) at the point of identification of disease, and 129 NSCLC patients and 83 healthy controls at the validation stage using reverse transcription‑quantitative polymerase chain reaction. Receiver operating characteristics (ROC) curves were generated for each possible combination of the miRNAs. We observed that the expression of plasma miR‑145, miR‑20a, miR‑21 and miR‑223 was significantly increased in the early‑stage NSCLC samples compared with controls. miRNAs have significant diagnostic value for early‑stage NSCLC. Combined ROC analyses using these four miRNAs revealed an elevated area under the ROC curve (AUC) of 0.897, with a sensitivity and specificity of 81.8 and 90.1%, respectively. This AUC helped in distinguishing early‑stage NSCLC. Furthermore, the levels of the four plasma miRNAs were significantly decreased following surgery (P<0.05). Altered expression of miR‑145, miR‑20a, miR‑21 and miR‑223 in plasma are of tumor origin, and the four miRNAs may represent potential novel non‑invasive biomarkers for early‑stage NSCLC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, et al: Non-small cell lung cancer. J Natl Compr Canc Netw. 8:740–801. 2010.PubMed/NCBI
3	Crinò L, Weder W, van Meerbeeck J and Felip E: ESMO Guidelines Working Group: Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 21:(Suppl 5). v103–v115. 2010. View Article : Google Scholar : PubMed/NCBI
4	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
5	Swensen SJ, Jett JR, Hartman TE, Midthun DE, Mandrekar SJ, Hillman SL, Sykes AM, Aughenbaugh GL, Bungum AO and Allen KL: CT screening for lung cancer: five-year prospective experience. Radiology. 235:259–265. 2005. View Article : Google Scholar : PubMed/NCBI
6	Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabrò E, Croce CM, Pastorino U and Sozzi G: MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA. 108:3713–3718. 2011. View Article : Google Scholar : PubMed/NCBI
7	Chen X, Hu Z, Wang W, Ba Y, Ma L, Zhang C, Wang C, Ren Z, Zhao Y, Wu S, et al: Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel non-invasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer. 130:1620–1628. 2012. View Article : Google Scholar : PubMed/NCBI
8	Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
9	Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
10	Keller A, Leidinger P, Gislefoss R, Haugen A, Langseth H, Staehler P, Lenhof HP and Meese E: Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis. RNA Biol. 8:506–516. 2011. View Article : Google Scholar : PubMed/NCBI
11	Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, Guarnera M, Liao J, Chou A, Lu CL, et al: Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest. 91:579–587. 2011. View Article : Google Scholar : PubMed/NCBI
12	Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
13	Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabrò E, Croce CM, Pastorino U and Sozzi G: MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA. 108:3713–3718. 2011. View Article : Google Scholar : PubMed/NCBI
14	Silva J, Garcia V, Zaballos Á, Provencio M, Lombardía L, Almonacid L, García JM, Domínguez G, Peña C, Diaz R, et al: Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. Eur Respir J. 37:617–623. 2011. View Article : Google Scholar : PubMed/NCBI
15	Tsim S, O'Dowd CA, Milroy R and Davidson S: Staging of non-small cell lung cancer (NSCLC): a review. Respir Med. 104:1767–1774. 2010. View Article : Google Scholar : PubMed/NCBI
16	Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP and Wei WI: Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res. 14:2588–2592. 2008. View Article : Google Scholar : PubMed/NCBI
17	Huang Z, Huang D, Ni S, Peng Z, Sheng W and Du X: Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 127:118–126. 2010. View Article : Google Scholar : PubMed/NCBI
18	Kroh EM, Parkin RK, Mitchell PS and Tewari M: Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 50:298–301. 2010. View Article : Google Scholar : PubMed/NCBI
19	Liu CJ, Kao SY, Tu HF, Tsai MM, Chang KW and Lin SC: Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis. 16:360–364. 2010. View Article : Google Scholar : PubMed/NCBI
20	Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi K, Fujiwara H, et al: Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer. 102:1174–1179. 2010. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Russ R and Slack FJ: Cigarette-smoke-induced dysregulation of MicroRNA expression and its role in lung carcinogenesis. Pulm Med. 2012:7912342012. View Article : Google Scholar : PubMed/NCBI
23	Wu X, Piper-Hunter MG, Crawford M, Nuovo GJ, Marsh CB, Otterson GA and Nana-Sinkam SP: MicroRNAs in the pathogenesis of lung cancer. J Thorac Oncol. 4:1028–1034. 2009. View Article : Google Scholar : PubMed/NCBI
24	Swensen SJ, Jett JR, Sloan JA, Midthun DE, Hartman TE, Sykes AM, Aughenbaugh GL, Zink FE, Hillman SL, Noetzel GR, et al: Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med. 165:508–513. 2002. View Article : Google Scholar : PubMed/NCBI
25	Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H and Quoix E: Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest. 108:163–169. 1995. View Article : Google Scholar : PubMed/NCBI
26	Nisman B, Lafair J, Heching N, Lyass O, Baras M, Peretz T and Barak V: Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Cancer. 82:1850–1859. 1998. View Article : Google Scholar : PubMed/NCBI
27	Andersen M, Grauslund M, Ravn J, Sørensen JB, Andersen CB and Santoni-Rugiu E: Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma. J Mol Diagn. 16:418–430. 2014. View Article : Google Scholar : PubMed/NCBI
28	Zheng H, Zhang L, Zhao Y, Yang D, Song F, Wen Y, Hao Q, Hu Z, Zhang W and Chen K: Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One. 8:e778532013. View Article : Google Scholar : PubMed/NCBI
29	Wang RJ, Zheng YH, Wang P and Zhang JZ: Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer. Int J Clin Exp Pathol. 8:765–771. 2015.PubMed/NCBI
30	Foss KM, Sima C, Ugolini D, Neri M, Allen KE and Weiss GJ: miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol. 6:482–488. 2011. View Article : Google Scholar : PubMed/NCBI
31	Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
32	Capodanno A, Boldrini L, Proietti A, Alì G, Pelliccioni S, Niccoli C, D'Incecco A, Cappuzzo F, Chella A, Lucchi M, et al: Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features. Int J Oncol. 43:765–774. 2013.PubMed/NCBI
33	Yang M, Shen H, Qiu C, Ni Y, Wang L, Dong W, Liao Y and Du J: High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer. 49:604–615. 2013. View Article : Google Scholar : PubMed/NCBI
34	O'Donnell KA, Wentzel EA, Zeller KI, Dang CV and Mendell JT: c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 435:839–843. 2005. View Article : Google Scholar : PubMed/NCBI
35	Chen Z, Zeng H, Guo Y, Liu P, Pan H, Deng A and Hu J: miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res. 29:1512010. View Article : Google Scholar : PubMed/NCBI
36	Zou C, Xu Q, Mao F, Li D, Bian C, Liu LZ, Jiang Y, Chen X, Qi Y, Zhang X, et al: MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle. 11:2137–2145. 2012. View Article : Google Scholar : PubMed/NCBI
37	Mar-Aguilar F, Mendoza-Ramirez JA, Malagón-Santiago I, Espino-Silva PK, Santuario-Facio SK, Ruiz-Flores P, Rodríguez-Padilla C and Reséndez-Pérez D: Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers. 34:163–169. 2013. View Article : Google Scholar : PubMed/NCBI
38	Ng EK, Li R, Shin VY, Jin HC, Leung CP, Ma ES, Pang R, Chua D, Chu KM, Law WL, et al: Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One. 8:e531412013. View Article : Google Scholar : PubMed/NCBI
39	Haneklaus M, Gerlic M, O'Neill LA and Masters SL: miR-223: infection, inflammation and cancer. J Intern Med. 274:215–226. 2013. View Article : Google Scholar : PubMed/NCBI
40	Nian W, Ao X, Wu Y, Huang Y, Shao J, Wang Y, Chen Z, Chen F and Wang D: miR-223 functions as a potent tumor suppressor of the Lewis lung carcinoma cell line by targeting insulin-like growth factor-1 receptor and cyclin-dependent kinase 2. Oncol Lett. 6:359–366. 2013.PubMed/NCBI
41	Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, et al: Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 141:672–675. 2008. View Article : Google Scholar : PubMed/NCBI
42	Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J and Kerin MJ: Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 251:499–505. 2010. View Article : Google Scholar : PubMed/NCBI